Imagine…one day soon the CEO responsible for bringing to patients the best Alz drug to date , was for years called the worst CEO of Biotech by impatient/short peeps.
Actually credibility is important. Turns out delivering on approvals is more important in Anavex's case.
At this point in time Missling's credibility is based on timelines proclaimed by Missling and he has not done very well on delivering on his self established timelines. That is clear to all.
Delivering on approvals will reestablish Misslings credibility way beyond the missed timelines.
So at the moment Missling's credibility has taken a hit. I suggest this is a short term problem. If the company fails to deliver approvals then Missling's credibility takes a massive long term whack.
If the company obtains Rett approval Missling will be suddenly rehabilitated. If the company obtains AD approval the history of Missling's credibility will be completely rewritten with the benefit of hindsight.
The story is still being written. How the 4th act plays out is still a mystery. You invest your money based on how you evaluate the incomplete information.
News 
Market Data 
Discover 
